Diorasis Therapeutics

Executive Summary

Diorasis Therapeutics is a preclinical-stage biotechnology company developing a first-in-class gene therapy for open-angle glaucoma, the leading cause of irreversible blindness worldwide. The company’s lead program targets the trabecular meshwork, aiming to restore the natural outflow of aqueous humor and thereby achieve durable intraocular pressure (IOP) reduction with a single administration. Unlike current treatments that require daily eye drops or repeated procedures, Diorasis’ approach addresses the underlying pathology of elevated IOP, offering the potential for a one-time, disease-modifying therapy. Based in Boston, Massachusetts, and founded in 2020, the company has completed initial proof-of-concept studies in animal models and is advancing toward IND-enabling activities. The gene therapy platform leverages an adeno-associated virus (AAV) vector to deliver a therapeutic transgene that modulates extracellular matrix dynamics in the trabecular meshwork, with the goal of long-term IOP normalization. Although still in early preclinical development, Diorasis Therapeutics addresses a significant unmet need in glaucoma care, where compliance with topical medications is poor and surgical interventions carry risks. The company’s focus on the trabecular meshwork—the primary site of outflow resistance in open-angle glaucoma—positions it as a potential first- or best-in-class option. However, the timeline to clinical proof-of-concept remains extended, and the inherent risks of gene therapy (immunogenicity, durability, manufacturing) apply. The company has not disclosed financing details, but the capital-intensive nature of gene therapy development suggests that securing Series A or even seed funding will be critical to reach clinical trials. A successful IND filing or early clinical data would be transformative.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling toxicology and biodistribution studies60% success
• Q2 2027Series A financing round to support IND filing50% success